Research ArticleArticle
Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions
Isabel Castrejón, Maxime Dougados, Bernard Combe, Bruno Fautrel, Francis Guillemin and Theodore Pincus
The Journal of Rheumatology April 2016, jrheum.141586; DOI: https://doi.org/10.3899/jrheum.141586
Isabel Castrejón
From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France. Supported by Health Report Services Inc. An unrestricted grant from Merck Sharp and Dohme was allocated for the first 5 years of the ESPOIR cohort. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, AbbVie, Pfizer, and Roche also supported the ESPOIR cohort. Dr. Pincus is president of Health Report Services Inc., which owns a copyright and a trademark for MDHAQ and RAPID3. I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. Address correspondence to Dr. T. Pincus, Division of Rheumatology, Rush University Medical Center, 1161 West Harrison St., Chicago, Illinois 60606, USA. E-mail: tedpincus@gmail.com. Accepted for publication March 1, 2016.
Maxime Dougados
From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France. Supported by Health Report Services Inc. An unrestricted grant from Merck Sharp and Dohme was allocated for the first 5 years of the ESPOIR cohort. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, AbbVie, Pfizer, and Roche also supported the ESPOIR cohort. Dr. Pincus is president of Health Report Services Inc., which owns a copyright and a trademark for MDHAQ and RAPID3. I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. Address correspondence to Dr. T. Pincus, Division of Rheumatology, Rush University Medical Center, 1161 West Harrison St., Chicago, Illinois 60606, USA. E-mail: tedpincus@gmail.com. Accepted for publication March 1, 2016.
Bernard Combe
From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France. Supported by Health Report Services Inc. An unrestricted grant from Merck Sharp and Dohme was allocated for the first 5 years of the ESPOIR cohort. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, AbbVie, Pfizer, and Roche also supported the ESPOIR cohort. Dr. Pincus is president of Health Report Services Inc., which owns a copyright and a trademark for MDHAQ and RAPID3. I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. Address correspondence to Dr. T. Pincus, Division of Rheumatology, Rush University Medical Center, 1161 West Harrison St., Chicago, Illinois 60606, USA. E-mail: tedpincus@gmail.com. Accepted for publication March 1, 2016.
Bruno Fautrel
From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France. Supported by Health Report Services Inc. An unrestricted grant from Merck Sharp and Dohme was allocated for the first 5 years of the ESPOIR cohort. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, AbbVie, Pfizer, and Roche also supported the ESPOIR cohort. Dr. Pincus is president of Health Report Services Inc., which owns a copyright and a trademark for MDHAQ and RAPID3. I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. Address correspondence to Dr. T. Pincus, Division of Rheumatology, Rush University Medical Center, 1161 West Harrison St., Chicago, Illinois 60606, USA. E-mail: tedpincus@gmail.com. Accepted for publication March 1, 2016.
Francis Guillemin
From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France. Supported by Health Report Services Inc. An unrestricted grant from Merck Sharp and Dohme was allocated for the first 5 years of the ESPOIR cohort. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, AbbVie, Pfizer, and Roche also supported the ESPOIR cohort. Dr. Pincus is president of Health Report Services Inc., which owns a copyright and a trademark for MDHAQ and RAPID3. I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. Address correspondence to Dr. T. Pincus, Division of Rheumatology, Rush University Medical Center, 1161 West Harrison St., Chicago, Illinois 60606, USA. E-mail: tedpincus@gmail.com. Accepted for publication March 1, 2016.
Theodore Pincus
From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France. Supported by Health Report Services Inc. An unrestricted grant from Merck Sharp and Dohme was allocated for the first 5 years of the ESPOIR cohort. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, AbbVie, Pfizer, and Roche also supported the ESPOIR cohort. Dr. Pincus is president of Health Report Services Inc., which owns a copyright and a trademark for MDHAQ and RAPID3. I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. Address correspondence to Dr. T. Pincus, Division of Rheumatology, Rush University Medical Center, 1161 West Harrison St., Chicago, Illinois 60606, USA. E-mail: tedpincus@gmail.com. Accepted for publication March 1, 2016.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions
Isabel Castrejón, Maxime Dougados, Bernard Combe, Bruno Fautrel, Francis Guillemin, Theodore Pincus
The Journal of Rheumatology Apr 2016, jrheum.141586; DOI: 10.3899/jrheum.141586
Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions
Isabel Castrejón, Maxime Dougados, Bernard Combe, Bruno Fautrel, Francis Guillemin, Theodore Pincus
The Journal of Rheumatology Apr 2016, jrheum.141586; DOI: 10.3899/jrheum.141586